Created at	Source	Raw Value	Validated value
April 29, 2021, 10:18 a.m.	usa	Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.;Phase II - IIBR-100 Immunogenicity by determining neutralizing antibody titers to SARS-CoV-2	Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.;Phase II - IIBR-100 Immunogenicity by determining neutralizing antibody titers to SARS-CoV-2
Oct. 30, 2020, 11:31 p.m.	usa	Phase II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline).;Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.	Phase II - IIBR-100 Immunogenicity as determined by GMT, GMFR, Seroconversion rates of the neutralizing antibody titers to SARS-CoV-2 per group at 28 days following last vaccination (in relation to Day 0-baseline).;Phase I and II - The number, grade and percentage of study participants who experience any study injection-associated AEs or SAEs.